The Latest
-
Trump calls for 50% tariffs on EU
The duties are slated to take effect July 9 as the bloc and the U.S. reengage on trade talks, the president said.
Updated May 27, 2025 -
Why Medtronic plans to spin out its diabetes business
While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on segments with higher margins.
-
Cost cuts, production shifts: How medtech firms are managing tariffs
Many companies forecast specific tariff charges. Then the White House and China agreed to a 90-day pause in their trade standoff.
-
Stryker wins FDA clearance for minimally invasive back pain treatment
The company will compete with a device Boston Scientific acquired for $850 million.
-
House passes reconciliation bill with massive Medicaid cuts
Speaker Mike Johnson negotiated a number of last minute changes to the megabill to get it across the finish line, including moving up the start date for Medicaid work requirements.
-
Medtronic plans to spin off diabetes business within 18 months
CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.
-
AI in medtech is booming. Track new devices here.
The Food and Drug Administration has authorized more medical devices that incorporate artificial intelligence. Keep track of the latest developments in this database.
-
Merit buys hemostatic device maker Biolife for $120M
Merit CEO Fred Lampropoulos said Biolife’s StatSeal and WoundSeal devices “address an estimated $350 million global market opportunity.”
-
FDA sets stricter approval standards for COVID vaccines
The agency will now require randomized, controlled data before approving new COVID shots for healthy children and adults, Commissioner Martin Makary and top vaccine official Vinay Prasad wrote in NEJM.
-
Teal posts data on newly approved at-home cancer screening device
Self-collection correctly identified 95.2% of HPV samples that are associated with increased cancer risk.
-
J&J subsidiary ordered to pay $147M for violating antitrust rules
A jury found that Biosense Webster withheld services to hospitals using reprocessed catheters.
-
Women’s health faces growing headwinds, despite jump in venture investment
While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.
-
FDA clears first blood test to aid Alzheimer’s diagnosis
The FDA cleared the test for the early detection of amyloid plaques associated with Alzheimer’s in people aged 55 years and older with signs and symptoms of the disease.
-
Regeneron wins bid to buy 23andMe out of bankruptcy
The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.
-
EndoQuest, Virtuoso begin clinical trials for surgical robots
EndoQuest Robotics completed two procedures with its endoluminal system, while Virtuoso Surgical successfully performed bladder lesion excision in six patients.